The senescence journey in cancer immunoediting

被引:19
|
作者
Zingoni, Alessandra [1 ]
Antonangeli, Fabrizio [2 ]
Sozzani, Silvano [1 ]
Santoni, Angela [1 ,3 ]
Cippitelli, Marco [1 ]
Soriani, Alessandra [1 ]
机构
[1] Sapienza Univ Rome, Fdn Cenci Bolognetti, Ist Pasteur Italia, Dept Mol Med, I-00161 Rome, Italy
[2] Natl Res Council CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy
[3] IRCCS Neuromed, I-86077 Pozzilli, Italy
关键词
Cancer; Senescence; SASP; Immunoediting; Immunosurveillance; Dormancy; Senotherapy; MESENCHYMAL STROMAL CELLS; NF-KAPPA-B; CELLULAR SENESCENCE; T-CELLS; DNA-DAMAGE; SECRETORY PHENOTYPE; TUMOR DORMANCY; PROMOTES SENESCENCE; ADAPTIVE IMMUNITY; NKG2D LIGANDS;
D O I
10.1186/s12943-024-01973-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in the tumor microenvironment can also promote tumor progression favoring the outgrowth of cancers capable of escaping immune control, in a process termed cancer immunoediting. This process, which has been classified into three phases, i.e. "elimination", "equilibrium" and "escape", is influenced by several cancer- and microenvironment-dependent factors. Senescence is a cellular program primed by cells in response to different pathophysiological stimuli, which is based on long-lasting cell cycle arrest and the secretion of numerous bioactive and inflammatory molecules. Because of this, cellular senescence is a potent immunomodulatory factor promptly recruiting immune cells and actively promoting tissue remodeling. In the context of cancer, these functions can lead to both cancer immunosurveillance and immunosuppression. In this review, the authors will discuss the role of senescence in cancer immunoediting, highlighting its context- and timing-dependent effects on the different three phases, describing how senescent cells promote immune cell recruitment for cancer cell elimination or sustain tumor microenvironment inflammation for immune escape. A potential contribution of senescent cells in cancer dormancy, as a mechanism of therapy resistance and cancer relapse, will be discussed with the final objective to unravel the immunotherapeutic implications of senescence modulation in cancer.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Cancer stem cell immunoediting by IFNγ
    Claudia Galassi
    Lorenzo Galluzzi
    Cell Death & Disease, 14
  • [22] Cancer Immunoediting: Immunologic Control and Sculpting of Cancer.
    Schreiber, R. D.
    CANCER RESEARCH, 2009, 69 (24) : 486S - 486S
  • [23] Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
    Vesely, Matthew D.
    Schreiber, Robert D.
    RENAISSANCE OF CANCER IMMUNOTHERAPY, 2013, 1284 : 1 - 5
  • [24] Immunoepigenetics: the unseen side of cancer immunoediting
    Germenis, A. E.
    Karanikas, V.
    IMMUNOLOGY AND CELL BIOLOGY, 2007, 85 (01): : 55 - 59
  • [25] Cancer immunoediting and "spontaneous" tumor regression
    Sengupta, Neel
    MacFie, Tammie S.
    MacDonald, Thomas T.
    Pennington, Daniel
    Silver, Andrew R.
    PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (01) : 1 - 8
  • [26] Immunoediting of cancer metastasis by NK cells
    Kyohei Nakamura
    Mark J. Smyth
    Nature Cancer, 2020, 1 : 670 - 671
  • [27] Antigen immunoselection as a mechanism of cancer immunoediting
    Matsushita, Hirokazu
    Vesely, Matthew
    Uppaluri, Ravindra
    Schreiber, Robert
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [28] Cancer stem cell immunoediting by IFNγ
    Galassi, Claudia
    Galluzzi, Lorenzo
    CELL DEATH & DISEASE, 2023, 14 (08)
  • [29] Cancer Immunoediting by the Innate Immune System
    Bui, Jack D.
    Vermi, William
    Ngolab, Jennifer
    Arthur, Cora
    White, J. Michael
    Uppaluri, Ravindra
    Schreiber, Robert D.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [30] Immunoediting of cancer metastasis by NK cells
    Nakamura, Kyohei
    Smyth, Mark J.
    NATURE CANCER, 2020, 1 (07) : 670 - 671